Connect with us

Cannabis News

Wisconsin GOP Lawmakers Are Divided On How To Regulate Hemp THC Products

Published

8 months ago

on

“We would like to work together … to make sure – in my humble opinion – that we protect our constituents, but also I think it’s necessary to protect an industry.”

Isiah Holmes, to the Wisconsin Examiner

Wisconsin lawmakers are pushing for competing visions for the state’s hemp future.

One proposal, (SB 682), was discussed at Thursday’s meeting of the Senate Agriculture and Revenue Committee.

The bill would create a regulatory framework for hemp-derived cannabis products that would keep the state’s hemp industry afloat despite a federal ban that takes effect in November. Without state intervention, or the federal government choosing to reverse course, hemp growers and distributors fear Wisconsin’s $700 million industry and about 3,500 jobs will disappear.

Sen. Patrick Testin (R-Stevens Point), chairman of the Agriculture and Revenue Committee, introduced the bipartisan hemp bill to his committee, which he authored with bipartisan support.

Testin’s legislation would define hemp as any cannabis plant that contains no more than 0.3 percent delta-9 THC (or the maximum concentration allowed by federal law of up to 1 percent, whichever is greater) and would define “hemp-derived cannabinoids” as compounds extracted from the hemp plant. THC concentrations would be determined using specific high-throughput test methods.

The bill would require Wisconsinites to be at least 21 years old to purchase hemp-derived cannabinoid products, which would require the products to undergo independent laboratory testing to ensure they contain the amount and type of cannabinoids described on the product label. This practice, known as true labeling, is something the hemp industry has called for in recent years.

The products could not be sold based on the invoice including contact information for the manufacturer or brand owner, serving sizes for each container of the product, including allergens, ingredient lists, labeled potency in milligrams, and required warnings. According to the bill, hemp-derived products could not contain more than 10 milligrams of THC in a single serving.

Testin said Thursday that the industrial hemp market was worth about $11 billion in 2025, and would grow to $48 billion by 2032.

In Wisconsin, such products are “generally allowed legally but unregulated,” Testin said.

“There is no state law that restricts sales to minors, regulates the potency or content of (hemp-derived cannabinoid products), or imposes labeling or packaging requirements.” Minnesota, Kentucky, Tennessee and other states have enacted their own regulations, Testin said. “Regulations are needed (to remove the current uncertainty about the cannabinoid status of hemp-derived products), to provide stability and certainty to companies looking to enter this segment of the economy, and to enforce public safety regulations.”

Testin and Republican Rep. Tony Kurtz (R-Wonewoc) have worked on hemp laws for Wisconsin since the federal Farm Bill passed in 2018.

“I actually grew hemp,” Kurtz said, recalling that in 2019 “it was kind of an open market.”

Kurtz and others who called him “bad actors” also rode the hemp wave throughout the hearing, seeing it as a “get-rich-quick scheme.” Kurtz said the hemp industry today is full of people who want to do the right thing, but the “bad actors” have persisted.

said Kurtz SB 682 It’s designed so Wisconsinites “know they’re getting the best product and what they’re getting.”

“If we do nothing, hemp will be illegal at the federal level … but it’s still going to be legal here in the state of Wisconsin. So it’s in our best interest to work together, to get a good compromise, to get some common sense legislation to make sure that — in my humble opinion — we protect our constituents, but also I think it’s necessary to protect an industry.”

While hemp would be illegal at the federal level, a state-level industry could operate similarly to the way some states have recreational or legalized cannabis programs, largely because the federal government has not cracked down on these industries.

Testin added, “Regardless of anyone’s thoughts on cannabis and cannabinoids, it’s here. And obviously, we have a lot of different perspectives on how we should move forward.”

He repeatedly blasted the “stupidity” of what he described as “our gentlemen” in Washington DC, but also criticized other hemp-related bills in Wisconsin. While some Republicans want to ban hemp products outright, others have different ideas about how a legal industry should be regulated.

Bill introduced by Sen. Eric Wimberger (R-Oconto). SB 681It would require licenses for manufacturers and distributors of hemp-derived cannabinoid products. The products would be sold under a three-tier system and would be regulated like alcohol under the Division of Alcoholic Beverages, a component of the Department of Revenue, which would be renamed the Division of Intoxicating Products.

Although Testin and Wimberger’s bill have garnered bipartisan support, Testin described Wimberger’s bill as a “dead bill” and “more dead than dead.”

Testin argued that SB 681 would over-regulate the hemp industry and lead to a monopolization effect where a small number of entities control who gets hemp permits, creating a competitive market and acting as a “good boys’ club.”

Sen. Sarah Keyeski (D-Lodi) highlighted the division among state Republicans over hemp and cannabis products, noting that Democrats are not the ones who support legalization and regulation.

The committee room was filled with people from across the hemp industry who listened to the conversation. When lawmakers asked how to ensure children don’t get intoxicating cannabis products, distributors and manufacturers pointed to age-verification software even for online sales, which require a photo and image of a driver’s license to accept an order.

Marketing of children’s products using cartoon-like advertising and attractive candy wrappers was discussed.

Some veterans have testified how hemp has helped them relieve pain, kick addictive pain killers, soothe PTSD symptoms, and help them relax their bodies to sleep.

Other testimony focused on the risk of crossing state lines into Michigan or Illinois to obtain cannabis to treat various medical conditions.

Hemp farmers insist they now need to know how a federal ban will affect them as they decide when or if to plant this spring.

Much of the public testimony was in favor of Testin’s bill, although some speakers said it should protect farmers and growers and expand the types of products to include beverages and gummies.

“Yes, we are now in a scenario where there are intoxicating hemp products,” Testin said. “But not just anything like beer, wine or alcohol, we need to put some sensible regulations in place, which is what this bill aims to do.”

“In terms of concerns about smoking or getting fat from these products,” Testin added, “it’s no different than people consuming too much stale fish fry or drinking too much beer on a Friday night. It’s one’s choice and responsibility, but at the same time, making sure we have some regulations in place.”

The hemp industry deserves to “grow and grow,” Testin said, adding that the public deserves protection and knowing that “this stuff isn’t falling into the hands of people it shouldn’t be, like children.”

This story was first published by the Wisconsin Examiner.

Brendan Cleak’s photo.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Related Topics:
Continue Reading

Cannabis News

Fluent to sell New York license and operations

Published

1 month ago

on

July 30, 2026

By











Fluent has entered into a definitive agreement to sell Etain, LLC, the Company’s New York-based operating entity. The purchase agreement was signed on July 22, 2026. The transaction provides for the sale of Etain’s Registered Entity license, certain of the Company’s New York operating assets and related New York leases for cash, subject to customary purchase price adjustments.

The Company believes the Transaction advances its strategic objectives and expects the Transaction to comply with applicable regulatory requirements in connection with the Company’s previously announced plan of arrangement for Vireo Growth Inc. (the “Deal”) while providing for an orderly transition of the New York operations to an experienced operator committed to serving patients and consumers.

Completion of the free transaction is subject to closing conditions, including, among other customary conditions, approval of the change in ownership by the New York State Cannabis Control Board and the completion of all conditions to the completion of the Agreement.

For more information:
FLUENT Corp
getfluent.com/










Continue Reading

Cannabis News

Marijuana Has ‘Horrific Health Risks’ And No Medical Value, Former Trump Attorney General Claims

Published

1 month ago

on

July 30, 2026

By

A former US attorney general who served in President Donald Trump’s first term says marijuana poses “tremendous health risks,” has no medical value and should not be rescheduled under federal law.

“Marijuana redistricting would create a false impression that it is safe, reduce penalties for illegally selling the drug, and provide a large tax windfall to those who legally supply it,” William Barr wrote in a Wednesday op-ed for The Washington Post, Kevin Sabet, CEO of the prohibitionist organization Smart Approaches to Marijuana. “That would be a disaster.”

The opinion comes as the Trump administration moves forward with cannabis reregulation.

According to an order issued in April by US Attorney General Todd Blanche, Marijuana products regulated by a state medical cannabis license were immediately changed from Schedule I As did marijuana products approved by the Food and Drug Administration (FDA) under Schedule III of the Controlled Substances Act (CSA).

an administrator The hearing is looking at the broader rescheduling of marijuanawith The Drug Enforcement Administration (DEA) has been tasked with advocating for cannabis reform highlighting the testimony about the medical benefits of marijuana and its relative safety compared to other substances such as alcohol and opioids. It included appearances by a Food and Drug Administration (FDA) scientist and a doctor from New Hampshire. Medical marijuana provides relief to pain patients and can serve as an alternative to opioids.

But Sabet and Barr, who served as Trump’s attorney general from 2019-2020, argued that “the evidence presented at the hearing did not support the rescheduling of marijuana” and instead “confirmed what decades of data have shown: raw marijuana has no scientifically established medical value and is highly susceptible to abuse.”

After the parties to the hearing have filed termination rights, the DEA administrative law judge overseeing the proceedings will make a recommendation regarding rescheduling, and the agency administrator will make a final decision.

DEA Administrator Terrance Cole only organizations and individuals opposed to marijuana reform have been invited to the hearing as a designated participant – telling supporters that they do not meet the definition of “interested person” to participate because they have not been “affected or prejudiced by any rule or proposed rule that may be issued.”

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

The former attorney general’s new opinion says “the stakes couldn’t be higher”, arguing that “marijuana today is more dangerous than ever” and that it is “addictive”, throwing out a list of alleged harm to mental and physical health.

“These unhealthy effects are a predictable result of a powerful and addictive drug being normalized, commercialized and marketed as a medicine,” Barr and Sabet say. “It would be one thing if marijuana had medical value. But there is no credible evidence that marijuana is an effective treatment for any medical condition, despite the millions of dollars spent trying to prove otherwise.”

The Department of Health and Human Services (HHS) published a 252 analysis in 2023 that concluded that marijuana had accepted medical value and should be rescheduled.

The new opposition piece also says that “rescheduling would unlock enormous revenue for the corporate marijuana industry by bringing it into a category that has not been covered by a longstanding reduction in federal drug tax deductions,” referring to a law known as 280E, which repeals Sections I and II.

“This, in turn, would allow the industry to spend even more on advertising and marketing to young people,” Barr and Sabet. he wroteArguing that “those who would lose this dragon in society are laying the foundations for another Big Tobacco”.

The Sabet organization, SAM, is one of several parties Challenging the Marijuana Redistricting Process which have been upheld by a federal Court of Appeals. those separate parts State attorneys general have filed lawsuits against cannabis reform, Opponents of marijuana legalization and a a cannabis-based biopharmaceutical corporation.

SAM’s lawsuit was signed by attorneys at Torridon Law PLLC, where Barr is a partner.

The team announced in January that it was Hiring Barr’s firm to fight cannabis rescheduling After Trump signed an executive order directing officials to quickly complete the process.

During the first Trump administration, Barr was accused by a Justice Department official Directing improper anti-company investigations into multiple cannabis company mergers– Accounting for almost a third of the division’s cases in 2019.

Several Democratic members of Congress introduced a resolution calling for an investigation into Barr’s possible impeachment, saying “abused the power of his office” to improperly investigate marijuana businesses while engaging in other allegedly illegal conduct.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading

Cannabis News

How much red light does cannabis really need?

Published

2 months ago

on

July 26, 2026

By

When growers pull out two LED fixtures side by side, the first number they usually discuss is percent red. This is an easy specification to fix. They are efficient at producing red photons and incredibly efficient at photosynthesis, and cannabis eats away at the flower. So more red must be better, right?

Not so simple. Red is an input to a spectrum, and the spectrum is an input to a room. There is no single spectrum that wins everywhere. An indoor room pushes hard, a greenhouse that soaks up sunlight, a temperamental cultivar, and aggressive yields call for something different. Knowing what each light strip actually does allows you to choose a tool that fits your grow instead of one that just has a big number on the sales page.

© JumpLights

Blue: structure
Blue (approximately 400-500 nm) gives shape to the plant. It maintains dense growth, strong stems, tight internodes and allows it to develop as desired. It also encourages stomatal opening, so the plant manages water and gas exchange better. Get blue and you’ve built a plant that can carry heavy flowers with no problem.

Green: access
Green was eliminated as the wavelength is “reflected” by plants. It turns out that it does a real job. Blue and red are absorbed above; the green goes deep into the fat and reaches the leaves that are never touched by the above photons. In a compact room, it’s the difference between plants photosynthesising from the top down and those that work only from the top. Green won’t replace your red or blue, but it does carry usable light where they can’t reach.

Red: engine
Red is the horse of the flower. It absorbs as efficiently as anything in the spectrum, and is responsible for most of the biomass you’re after. Redder generally means faster flower development, more weight and better efficiency per watt.

But red has a ceiling, and it’s tied to what you run. Push PPFD upwards with a heavy red spectrum and some cultivars begin to whiten at the top: the flower should be dense with pale, washed tips. Genetics, intensity, barrel temperature and your general environment all feed into it. If you’re using aggressive light levels, a lower red spectrum will buy you room before that becomes a problem, leaving you almost no photosynthetic punch to get it.

Far Red: More than Emerson
Far-red (700-750 nm) appears in more devices every year. It contributes little to photosynthesis on its own, but it moves plant morphology and works with red through the Emerson Enhancement Effect. Used properly, it helps to deepen the light, encourage uniformity of the canopy and encourage the response of the bloom. The key word is small. A touch of far red rounds out a spectrum; he’s not there to make a show.

Matching the red percentage with the room
Cannabis addresses the entire spectrum, not a line on a spec sheet. Reds cause flowers, but blues, greens and crimsons give the plant something it needs. Where you land in red refers to how you grow.

A lower red spectrum (30-40%) captures more blue and green, gives you better morphology, reduces the risk of photobleaching, and holds up when you’re running extreme PPFD. Moderate spectrum (40-55%) is the sweet spot in commercial greenhouses: strong photosynthetic efficiency, strong flowering, balanced growth. A high-red spectrum (70%+) makes the most sense in a greenhouse, where the sun is already giving you lots of blue and green and your supplemental light can cast effective red to fill the gap.

Where does the ETS MAX series fit in?
This is the thinking behind the JumpLights ETS MAX series. Instead of forcing a spectrum into each room, it rarely comes up because a greenhouse and a high PPFD indoor flower room are not the same problem.

  • ETS MAX 4C41% red: for indoor rooms operating at very high intensity, where photobleaching is a real risk. The wider, red bottom balance allows you to push the tops without overcooking them
  • ETS MAX 4A48% red: balanced internal spectrum that maintains high output while controlling bleaching.
  • ETS MAX 5B57% Red: A high-performance indoor option. Moderate red, marked with efficiency and flower at the same time, up to 3,450 μmol/s, with efficiency that holds the spectrum.
  • ETS MAX 7A76% red: built for the greenhouse. The sun already supplies blue and green, so this leans heavily on the complementary red, up to 3,900 μmol/s in the infrastructure most greenhouses already have in place.

Bottom line
Choosing an activity is not a competition for the highest red number. The winning spectrum is the one that matches your environment, your intensity, your genetics, and what you’re trying to produce. Combine spectrum, intensity, environmental control, light distribution and genetics, and you’ve got a lighting strategy. Keep a spec isolated and all you’ve got is a bright room.

The ETS MAX line was created around this idea: choose the spectrum of the room you actually have, indoor or greenhouse, and let the device work with your grow rather than against it.

For more information:
JumpLights
www.jumplights.com

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media